JP2020505335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505335A5 JP2020505335A5 JP2019537216A JP2019537216A JP2020505335A5 JP 2020505335 A5 JP2020505335 A5 JP 2020505335A5 JP 2019537216 A JP2019537216 A JP 2019537216A JP 2019537216 A JP2019537216 A JP 2019537216A JP 2020505335 A5 JP2020505335 A5 JP 2020505335A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- acceptable salt
- physiologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023061291A JP2023098938A (ja) | 2017-01-06 | 2023-04-05 | ウイルス |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1700259.3A GB201700259D0 (en) | 2017-01-06 | 2017-01-06 | Virus |
| GB1700259.3 | 2017-01-06 | ||
| GBGB1716047.4A GB201716047D0 (en) | 2017-10-02 | 2017-10-02 | Virus |
| GB1716047.4 | 2017-10-02 | ||
| PCT/GB2018/050021 WO2018127702A1 (en) | 2017-01-06 | 2018-01-05 | Virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061291A Division JP2023098938A (ja) | 2017-01-06 | 2023-04-05 | ウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505335A JP2020505335A (ja) | 2020-02-20 |
| JP2020505335A5 true JP2020505335A5 (enExample) | 2021-02-12 |
| JP7728634B2 JP7728634B2 (ja) | 2025-08-25 |
Family
ID=61022367
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537216A Active JP7728634B2 (ja) | 2017-01-06 | 2018-01-05 | ウイルス |
| JP2023061291A Pending JP2023098938A (ja) | 2017-01-06 | 2023-04-05 | ウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061291A Pending JP2023098938A (ja) | 2017-01-06 | 2023-04-05 | ウイルス |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12016949B2 (enExample) |
| EP (1) | EP3565591A1 (enExample) |
| JP (2) | JP7728634B2 (enExample) |
| KR (1) | KR20190104051A (enExample) |
| CN (1) | CN110621350A (enExample) |
| AU (1) | AU2018206304A1 (enExample) |
| BR (1) | BR112019014004A2 (enExample) |
| CA (1) | CA3048313A1 (enExample) |
| IL (1) | IL267785A (enExample) |
| MX (1) | MX2019008105A (enExample) |
| WO (1) | WO2018127702A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011234264B2 (en) | 2010-03-31 | 2016-02-04 | Stabilitech Ltd | Excipients for stabilising viral particles, polypeptides or biological material |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| US20200061210A1 (en) * | 2018-08-27 | 2020-02-27 | BioViva USA, Inc. | Novel method for gene therapy using intranasal administration of genetically modified viral vectors |
| JP7436274B2 (ja) * | 2020-04-16 | 2024-02-21 | デンカ株式会社 | アデノウイルスの免疫測定方法及び免疫測定器具 |
| GB202104320D0 (en) | 2021-03-26 | 2021-05-12 | Iosbio Ltd | Enhancement of viral titres |
| CN113880723A (zh) * | 2021-11-15 | 2022-01-04 | 河南海尔希生物科技有限公司 | 一种盐酸甜菜碱的制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4296130A (en) | 1979-08-30 | 1981-10-20 | Herschler R J | Methylsulfonylmethane and methods of use |
| JPH11507231A (ja) | 1995-06-07 | 1999-06-29 | イェール ユニバーシティ | アデノ関連ウイルスベクターの経口送達 |
| US6616931B1 (en) | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| ATE374251T1 (de) | 1999-02-19 | 2007-10-15 | Engene Inc | Zusammensetzungen zur gentherapie von diabetes |
| EP2298357A1 (en) | 2000-03-13 | 2011-03-23 | Engene, Inc. | Compositions and methods for regulated protein expression in gut |
| US7226779B2 (en) | 2001-01-30 | 2007-06-05 | The United States Of America As Represented By The Department Of Health And Human Services | Hybrid adenoviral vector |
| WO2002101012A2 (en) | 2001-06-08 | 2002-12-19 | Children's Hospital Research Foundation | Regulation of transgene expression following aav transduction |
| WO2003039593A1 (en) | 2001-11-08 | 2003-05-15 | Akzo Nobel N.V. | Fowl adenovirus vaccine |
| JP4888876B2 (ja) | 2003-06-13 | 2012-02-29 | 田平 武 | アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター |
| US20060140908A1 (en) * | 2003-06-18 | 2006-06-29 | Ertl Hildegund C J | Methods for inducing an immune response via oral administration of an adenovirus |
| PL2002003T3 (pl) | 2005-05-27 | 2016-06-30 | Ospedale San Raffaele Srl | Wektor genetyczny zawierający mi-RNA |
| RU2008117396A (ru) | 2005-10-04 | 2009-11-10 | Альк-Абелло А/С (Dk) | Твердая вакцинная композиция |
| EA014757B1 (ru) * | 2006-02-28 | 2011-02-28 | Вэксарт, Инк. | Химерный аденовирусный вектор, иммуногенная композиция на его основе, способ индукции иммуного ответа с его помощью и выделенная нуклеиновая кислота |
| BRPI0915696B8 (pt) | 2008-11-07 | 2021-05-25 | Serum Institute Of India Ltd | composição de vacina de rotavírus liofilizada e método de preparar a referida composição |
| ES2612889T3 (es) * | 2008-12-22 | 2017-05-19 | Targovax Oy | Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos |
| DK2477652T3 (en) | 2009-09-16 | 2015-07-20 | Vaxart Inc | Immunization strategy for the prevention of infection H1Ni |
| AU2011234264B2 (en) * | 2010-03-31 | 2016-02-04 | Stabilitech Ltd | Excipients for stabilising viral particles, polypeptides or biological material |
| US10206960B2 (en) | 2010-03-31 | 2019-02-19 | Stabilitech Biopharma Ltd | Stabilisation of viral particles |
| EP2619224A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| US20120219590A1 (en) * | 2011-02-24 | 2012-08-30 | Paxvax, Inc. | Formulations useful for spray drying vaccines |
| GB201117233D0 (en) * | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| DK2908865T3 (en) | 2012-10-17 | 2019-01-28 | Vascular Biogenics Ltd | ADENOVIRUS THAT EXPRESSES A PHAS-CHIMARY AND ITS APPLICATION IN CANCER TREATMENT METHODS |
| CA2939581C (en) * | 2014-02-20 | 2024-01-23 | Vaxart, Inc. | Formulations for small intestinal delivery |
| WO2015128421A1 (en) * | 2014-02-28 | 2015-09-03 | Crucell Holland B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| GB201406569D0 (en) * | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| ES2832504T3 (es) * | 2015-06-12 | 2021-06-10 | Vaxart Inc | Formulaciones para administración de antígenos de norovirus y rsv en el intestino delgado |
| GB2562241B (en) * | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| CN108795984A (zh) * | 2018-07-05 | 2018-11-13 | 天津医科大学 | 一种利用腺病毒载体构建小肠降表达胰岛素大鼠模型的方法 |
-
2018
- 2018-01-05 KR KR1020197022985A patent/KR20190104051A/ko not_active Ceased
- 2018-01-05 BR BR112019014004-2A patent/BR112019014004A2/pt not_active Application Discontinuation
- 2018-01-05 CN CN201880006090.1A patent/CN110621350A/zh active Pending
- 2018-01-05 US US16/475,417 patent/US12016949B2/en active Active
- 2018-01-05 EP EP18701209.1A patent/EP3565591A1/en active Pending
- 2018-01-05 WO PCT/GB2018/050021 patent/WO2018127702A1/en not_active Ceased
- 2018-01-05 AU AU2018206304A patent/AU2018206304A1/en not_active Abandoned
- 2018-01-05 CA CA3048313A patent/CA3048313A1/en active Pending
- 2018-01-05 JP JP2019537216A patent/JP7728634B2/ja active Active
- 2018-01-05 MX MX2019008105A patent/MX2019008105A/es unknown
-
2019
- 2019-07-02 IL IL267785A patent/IL267785A/en unknown
-
2023
- 2023-04-05 JP JP2023061291A patent/JP2023098938A/ja active Pending
-
2024
- 2024-05-13 US US18/662,148 patent/US20240374509A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505335A5 (enExample) | ||
| ES2584430T3 (es) | Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles | |
| AP408A (en) | Vaccine composition containing adjuvants. | |
| US6852705B2 (en) | DNA vaccines for farm animals, in particular bovines and porcines | |
| ES2981241T3 (es) | Formas cristalinas de tenofovir alafenamida | |
| Mazumdar et al. | A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice | |
| KR101747987B1 (ko) | 단순 헤르페스 바이러스 백신 | |
| WO2020063370A2 (zh) | 免疫组合物及其制备方法与应用 | |
| CN1224422C (zh) | 含有白细胞介素il－12和单纯疱疹病毒抗原的疫苗 | |
| TW201446263A (zh) | 治療或預防人類免疫缺乏病毒感染之組合物及方法 | |
| JP2017532316A5 (enExample) | ||
| CA3048313A1 (en) | Virus | |
| CN109200270B (zh) | 一种能提高多肽疫苗对hpv感染肿瘤治疗效果的联合用药物及其应用 | |
| JP2024099746A (ja) | ワクチンアジュバントとしてのハロゲン化キサンテン | |
| Domingo et al. | Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D | |
| Wang et al. | Protection against genotype VII Newcastle disease virus challenge by a minicircle DNA vaccine coexpressing F protein and chicken IL-18 adjuvant | |
| JP2002523458A5 (enExample) | ||
| Basirnejad et al. | Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant | |
| Cooper et al. | Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junction | |
| RU2130779C1 (ru) | Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии | |
| RU2678981C2 (ru) | Композиция от бешенства, содержащая адъювант pika | |
| US20240182528A1 (en) | Modified chimeric coronavirus spike protein for enhancement of viral titers | |
| KR100825984B1 (ko) | 조사된 인간 ｂ형 간염 표면 항원을 발현하는 암세포를이용하여 종양을 치료하는 방법 및 상기 암세포를 포함하는종양치료용 약학적 조성물 | |
| EP3332809A1 (en) | Immunity induction promoting composition, and vaccine pharmaceutical composition | |
| US20200347036A1 (en) | Solid forms of an hiv protease inhibitor |